UC Davis Veterinary Clinical Trials

Assessing a Stem Cell Treatment for Myasthenia Gravis (MG) in Dogs

Help us treat dogs with Myasthenia Gravis!

Myasthenia Gravis (MG) is a rare neuromuscular disease that is the result of an immune system attack on structures critical for nerve to muscle signaling. Clinical signs include generalized weakness and muscle weakness around the eyes, limbs or airways. There is no cure though some dogs will go into spontaneous remission. Novel stem cell therapies offer new hope for dogs with MG. For this clinical trial, we hope that adding stem cell treatment along with standard pharmaceutical treatment and care for MG will improve symptoms of the disease.

Stem Cell Study
Any

Assessing a New Drug to Treat Heart Failure in Dogs with Myxomatous Mitral Valve Disease

Please talk to your veterinarian or bring your dog to the UC Davis VMTH Emergency Room for evaluation!

Myxomatous mitral valve disease is the most common cardiac disease and the leading cause of congestive heart failure in dogs. Reducing blood pressure is one strategy to help manage these patients. By reducing blood pressure, the heart can move blood forward more effectively, reducing fluid accumulation in the lungs that can result from this condition. However, available medications for this health emergency are extremely limited and currently available drugs often have extreme price volatility, low availability or unwanted side effects. Researchers will conduct a small clinical trial to evaluate the use of a new drug clevidipine to reduce blood pressure in client-owned dogs admitted to hospital. Finding a safe, affordable alternative drug that is readily available may help improve survival of critically ill canine patients requiring urgent care for heart failure.

Drug - Treatment

Circulating DNA in cats with hypertrophic cardiomyopathy and cardiogenic arterial thromboembolism

Help us look for a screening test to prevent clot formation in cats

Hypertrophic cardiomyopathy (HCM) is the most common heart disease in cats. About 20% of cats will develop clinical signs due to HCM. Of these complications, the most devastating is cardiogenic arterial thromboembolism (clot formation), otherwise known as, “saddle thrombus”, which is one of the most distressing emergencies for cat owners. This disease is complicated by the fact that most cats that develop saddle thrombus appear healthy and do not have heart murmurs. Veterinarians currently have limited abilities to test and treat cats at the greatest risk of forming saddle thrombus. For this reason, we hope to look for protein markers and free circulating DNA in the blood of cats with HCM and saddle thrombus. Free circulating DNA has been shown in humans, mice and dogs to promote clot formation and can be used as a treatment target. We, therefore, hope to further understand these findings by seeing if free circulating DNA in cats contribute to saddle thrombus in cats with HCM. This information will enable us to establish a screening test that will guide clinicians in identifying cats at risk of clot formation.

Observational
Any, age > 1 year old
Loading